Provider, payor ally to drive accountable care into central Pa.

Two healthcare organizations serving central Pennsylvania—a provider and a payor—are teaming up to form what they are calling an Accountable Care Arrangement (ACA). According to a joint release from PinnacleHealth and Capital BlueCross, the alliance will work to decrease utilization of acute-care services.

Under the arrangement, Capital BlueCross will provide dedicated nursing resources, access to technology and “critical analytics” to PinnacleHealth’s physicians.

The organizations said they will use population-based clinical data to deliver “highly personalized medical care, resulting in increased doctor-patient face time.”

The two further said the arrangement would enable “a more integrated approach to the delivery of medical services” to more than 25,000 patients, adding that it follows as an extension of a partnership they forged while rolling out a pilot for a patient-centered medical home in 2010.

Both Capital BlueCross, a licensee of the Blue Cross and Blue Shield Association, and PinnacleHealth, which runs multiple facilities orbiting four main campuses, are headquartered in Harrisburg.
Dave Pearson

Dave P. has worked in journalism, marketing and public relations for more than 30 years, frequently concentrating on hospitals, healthcare technology and Catholic communications. He has also specialized in fundraising communications, ghostwriting for CEOs of local, national and global charities, nonprofits and foundations.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.